MAPK3 and cancer: The involvement of constitutive ERK1/2 activation in the proliferation and tumoral progression has been largely reported in many cancer cells including malignant melanomas (7), human hepatocellular carcinoma (8), esophagogastric cancer (9), breast cancer (10), renal cell carcinomas (11) and leukemia (12).